FINTEPLA
PeakNDAORALSOLUTIONPriority Review
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FINTEPLA (fenfluramine) is an oral solution small molecule approved in June 2020 for rare seizure disorders, specifically Dravet syndrome and Lennox-Gastaut syndrome. It is a serotonin 5-HT1A and 5-HT7 receptor agonist that reduces seizure frequency in these severe pediatric epilepsy populations. The drug represents a significant therapeutic advance for patients with limited treatment options.
$18.0MPart D
Peak12.1 years to LOEProduct is in peak commercial phase with modest Part D spending (~$18M in 2023), indicating a niche orphan drug positioning; teams are likely focused on maximizing penetration within the rare epilepsy patient base.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FINTEPLA offers a specialized career opportunity in rare disease/orphan drug management, where success depends on deep relationships with a concentrated network of pediatric neurologists and epilepsy specialists. Roles on this product team require expertise in small patient populations, payer navigation, and highly regulated pediatric markets—valuable skills for long-term growth in specialty pharma.
Medical Science Liaison
Worked on FINTEPLA at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.